Personalized Diagnostics

Joseph Anderson, MD

• Jeffery Taubenberger, MD, PhD, of the NIH, Sequencing the 1918 Spanish Flu and What do we know About the Novel Coronavirus? - Episode 20

  Jul 12th 2020

  What can we learn from previous pandemics to apply to the current situation?
  
  What do we actually know to be true about the novel coronavirus?
  
  Jeffrey Taubenberger, MD, PhD, a physician-scientist and investigator at the National Institutes of Health, joins us to discuss his landmark work in sequencing the 1918 Spanish flu virus and to provide insights into the current novel coronavirus global pandemic.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=9W70RZWY-TM4PLDI

  15

  15

  0:00:00

  0:31:59

• BRUNO LARVOL, FOUNDER AND CEO OF LARVOL - PREVIEW 3

  Jul 12th 2020

  Change can be slow - particularly in #healthcare.
  
  Establishing clinical validity and clinical utility can be slow.
  
  Getting regulatory approvals can be slow.
  
  Gaining payor acceptance can be slow.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=Q4QRVAE-DEBXU5WM

  15

  15

  0:00:00

  0:00:43

• Bruno Larvol, Founder and CEO of Larvol - Preview 2

  Jul 12th 2020

  Where are we in this megatrend of precision #medicine?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=SXOCBRJ-ZW2BUIK9

  15

  15

  0:00:00

  0:02:10

• Bruno Larvol, Founder and CEO of Larvol - Preview 1

  Jul 12th 2020

  Since the human genome has been sequenced, it has become clear that the technology to sequence has far outstripped our capabilities to accurately classify and interpret genetic variants.
  
  It turns out that genetic variants are much more common than we ever suspected and many - in some cases most - variants are of uncertain significance.
  
  But is the attempt to accurately classify Variants of Uncertain Significance (VUS) a losing strategy?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8US52GQL-SGIUDI

  15

  15

  0:00:00

  0:01:46

• Bruno Larvol, Founder and CEO of the Healthcare Data Company, Larvol - Episode 19

  Jun 22nd 2020

  We have seen tremendous advances in sequencing technology. And the cost to sequence is going to zero, according to Moore's Law. More and more genes and gene sets are being correlated with clinical outcome and response to therapy.
  
  Is bioinformatics intelligence the missing link to realizing the promise of precision medicine?
  
  Will a company emerge as the Google or Amazon of cancer informatics?
  
  Our guest is Bruno Larvol, of the eponymous healthcare data company, Larvol.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=3887B60O-GSEXW29

  15

  15

  0:00:00

  0:34:37

• DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH - Preview 3

  Jun 22nd 2020

  "We have to evolve."
  
  Establishing a "gold standard" for real world evidence will allow us to move beyond what we can learn from the 4% of patients enrolled in clinical trials and allow #innovation to flourish.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=2KOBQMA-0O0MB1EM

  15

  15

  0:00:00

  0:01:04

• DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH -Preview 2

  Jun 22nd 2020

  Fewer than 4% of oncology patients ever make it onto a clinical trial. And these 4% may not even reflect the real-world patient experience.
  
  How can we use real world data in a rigorous and thoughtful way to come up with new standards of evidence to help move innovation forward?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=HCFST24F-I9HPVI

  15

  15

  0:00:00

  0:01:25

• DANE DICKSON, MD, FOUNDER AND CEO OF TAPROOT HEALTH -Preview 1

  Jun 22nd 2020

  There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.
  
  But is the existing infrastructure adequate to bring innovation into patient care?
  
  It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial. These trials, however, are extremely costly and time-consuming and generate only a limited number of conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.
  
  Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=E4YRYJ4L-G5VCXR

  15

  15

  0:00:00

  0:01:38

• DAne Dickson, MD, founder and CEO of Taproot Health - Episode 18

  Jun 7th 2020

  There’s no question that we are awash in promising new technologies with the potential to advance precision medicine.
  
  But is the existing infrastructure adequate to bring innovation into patient care?
  It's generally recognized that the highest levels of evidence are generated via the prospective randomized trial. These trials, however, are extremely costly and time-consuming and generate only limited conclusions from a small subset of patients which may not be truly reflective of the real-world patient experience.
  
  Will we be able to evolve and find new ways to generate high levels of evidence to move precision medicine forward?
  
  Dane Dixon, MD, of Taproot Health joins us in one of our most important episodes to date.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=7VG174Q4-J5G66R

  15

  15

  0:00:00

  0:35:10

• TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 4

  Jun 5th 2020

  The diagnostics #industry is very fragmented, in terms of testing laboratories, test developers, and testing methodologies used.
  
  Companion diagnostics testing for targeted therapies is still done by a variety of methodologies, including immunohistochemistry, FISH, RT-PCR, RNA expression analysis as well as next-generation sequencing, and others.
  
  The advent of next-generation #sequencing, as many predicted, has not - as of yet - led to a more unified approach to testing. Why is this?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=A2UAMI6Y-BQK6GVI

  15

  15

  0:00:00

  0:01:11

• TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 3

  Jun 5th 2020

  With the advent of next generation sequencing, we've gained the ability to test for nearly any and all genomic alterations – many or most of which are benign or of uncertain significance.
  
  And, believe it or not, we encounter many benign or uncertain alterations in tumor related genes.
  
  Targeted therapies have historically been developed with a relatively small number of alterations in mind. For example, KRAS testing focused originally only on codon 12 and 13 mutations. While, 90% of deleterious EGFR alterations in lung #cancer are either chromosome 19 deletion or the L858R mutation.
  
  Are we in danger of watering down the size of the effect in clinical trials for targeted therapies by trying to incorporate too many genomic alterations in their #design?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8DPLCSPL-6HCL3DI

  15

  15

  0:00:00

  0:00:56

• TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - PREVIEW 2

  Jun 5th 2020

  Will this be a golden #era for #diagnostics?
  
  Are we moving away from a model based on high-value #therapeutics and towards one based more on high-value diagnostics?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=17MR9RKV-7PJ02J4

  15

  15

  0:00:00

  0:00:33

• TRACY GEORGE, MD - EXECUTIVE DIRECTOR OF CLINICAL TRIALS AND PHARMADX AT ARUP LABORATORIES - Preview 1

  Jun 5th 2020

  September 25, 1998 - trastuzumab, one of the first targeted therapies with a companion diagnostic, received #FDA approval in breast #cancer.
  
  The commercially available IHC and FISH companion #diagnostics were not incorporated into the pivotal clinical trial. They had to be subsequently "developed" and validated by way of concordance studies (which were not stellar).
  
  Does this still happen today? Have we begun to appreciate the importance of embedding companion diagnostics directly into clinical trials?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=CXBSICLG-78K6GVI

  15

  15

  0:00:00

  0:00:30

• Tracy George, MD - Executive Director of clinical trials and pharmaDX at ARUP Laboratories - Episode 17

  May 21st 2020

  Over the past 20 years we've seen the development of approximately 40 indications for targeted therapies with a companion diagnostic. How can we continue to build on these successes and develop even more effective strategies for developing targeted therapies with companion diagnostics and incorporating diagnostics into clinical trials?
  
  Our guest is Tracy George, MD, Professor of Pathology at the University of Utah and the Executive Director of clinical trials and pharma DX at ARUP Laboratories.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=AE0VZF3M-TKPGB9

  15

  15

  0:00:00

  0:25:15

• DR. TOM STUBBS, CO-FOUNDER AND CEO OF CHRONOMICS - PREVIEW 3

  May 21st 2020

  We’ve all heard the term “epigenetics.” But what does it actually mean?
  
  #Epigenetics is the study of changes in organisms caused by modification of gene expression rather than alteration of the genetic code itself.
  
  It is somewhat of a catch-all term and does not apply to any one type of change or any one methodology for measuring these changes.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=6I2HPWT7-VXCG14I

  15

  15

  0:00:00

  0:00:21

• DR. TOM STUBBS, CO-FOUNDER AND CEO OF CHRONOMICS - PREVIEW 2

  May 21st 2020

  There appears to be a clear association between age and underlying chronic conditions such as #diabetes and #hypertension and the severity of a #covid19 illness.
  
  Can epigenetics inform us of our risk of acquiring acute or infectious illnesses such as Covid-19 and their severity?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=4KAXY3YK-Y7OUSOR

  15

  15

  0:00:00

  0:01:00

• Dr. Tom Stubbs, Co-Founder and CEO of Chronomics - Preview 1

  May 21st 2020

  How do we age?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=A8BMQI9I-VIMS4I

  15

  15

  0:00:00

  0:02:06

• Dr. Tom Stubbs, Co-founder and CEO of Chronomics - Episode 16

  May 8th 2020

  We've all heard the term biological age. But what does it mean exactly? How is it measured? And is it possible to "turn back the hands of time?"
  
  Does the key to health, wellness and longevity lie in epigenetics?
  
  We are joined by Dr. Tom Stubbs, Co- founder and CEO of Chronomics

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=7O0FYLOD-PHF47VI

  15

  15

  0:00:00

  0:25:57

• Hagenkord's Korner - Preview 2

  Apr 27th 2020

  Slow down - testing for SARS-CoV-2 is not as simple as it may seem.
  
  “What I really want to know is: if this test result is positive, what are the chances that my patient actually has the condition.
  
  “Sensitivity and specificity really have no utility in a practical everyday clinical setting.
  
  “You really want to know the positive predictive value and the negative predictive value.”

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=UK5HLDP-1ZG58KT9

  15

  15

  0:00:00

  0:03:04

• Hagenkord's Korner - preview 1

  Apr 27th 2020

  Slow down - testing for SARS-CoV-2 is complicated.
  
  Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.
  
  She joins us for this first installment of "Hagenkord's Korner."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=J7VP2A8J-9YSYVI

  15

  15

  0:00:00

  0:02:02

• RONDELL GRAHAM, M.B.B.S., HEAD OF GASTROINTESTINAL AND LIVER PATHOLOGY AT THE MAYO CLINIC - PREVIEW 4

  Apr 27th 2020

  Entrectinib and larotrectinib have been approved to treat tumors with fusions in the neurotrophic tropomyosin receptor kinase (NTRK) gene – irrespective of the tumor’s site of origin.
  
  These drugs are the second and third agents, overall, to have a tissue-agnostic indication approved by the FDA.
  
  The first was pembrolizumab, an immunotherapy agent, indicated for tumors with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) tumors in 2017.
  
  Have we finally reached the point where tumor biology has become a more important consideration than site of origin?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=BNB27JJQ-X3FECDI

  15

  15

  0:00:00

  0:00:50

• Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 3

  Apr 27th 2020

  Microsatellite instability testing in #colon #cancer has evolved considerably over the past several years. It began as a way to screen for Lynch #Syndrome, a heritable condition, which accounts for about 5% of colon cancers.
  
  MSI subsequently has been shown to be a prognostic factor in colon cancer.
  
  And in its most recent incarnation as a biomarker, it has been shown to be predictive for response to immunotherapy. Pembrolizumab has been approved for patients with microsatellite instability-high tumors.
  
  Interestingly, or perhaps counter-intuitively, patients with microsatellite unstable tumors actually have a better prognosis. Why is this?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=JPD73DZU-RN3IK9

  15

  15

  0:00:00

  0:01:03

• Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 2

  Apr 27th 2020

  Diagnostic Testing can be thought of as occurring in three phases:
  
  1. Pre-analytic phase - everything leading up to the actual testing, including properly filling out a requisition, blood draw, specimen handling, gross examination and tissue fixation
  
  2. Analytic phase - the actual testing itself, which is “flashy” and most people understand
  
  3. Post-analytic phase - results interpretation, report generation, communication with the ordering physician and planning for future testing
  
  If the pre-analytic phase is suboptimal, everything that follows may be unreliable or uninformative.
  
  Colloquially, this is known as “Garbage in, garbage out.”
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=J4B7EICS-JI3SOR

  15

  15

  0:00:00

  0:00:43

• Rondell Graham, M.B.B.S., Head of Gastrointestinal and Liver Pathology at the Mayo Clinic - Preview 1

  Apr 27th 2020

  It is not often we have a major paradigm shift in medicine.
  
  Albert Broders, MD, was a pathologist at the Mayo Clinic. Early in his career, he described tumor grading, showing for the first time that features in cancer specimens observed under the microscope could predict outcomes.
  
  This discovery was a massive paradigm shift, that quickly begat tumor staging and eventually the whole predictive biomarker field.
  
  Rondell Graham, Head of GI and Liver Pathology at the Mayo Clinic, joins us this week on The Personalized Diagnostics Podcast, where we discuss predictive and prognostic markers in colon cancer, molecular diagnostics, digital pathology, the future of targeted therapies and much more.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=4TAFH3A6-0UANHFR

  15

  15

  0:00:00

  0:00:36

• Hagenkord's Korner - SARS COV2 Testing

  Apr 24th 2020

  We are introducing a new feature: "Hagenkord's Korner."
  
  Jill Hagenkord, MD, FCAP is co-founder and CMO of MDisrupt, as well as previously serving as CMO at Invitae, Complete Genomics Inc., Color, and 23andMe.
  
  This week we will be discussing how we have been hearing relatively little from experts such as physicians, epidemiologists, virologists and statisticians during the current pandemic.
  
  We will also be discussing the pitfalls of testing and test development for SARS-CoV-2.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FGF1YA3K-SY8PVI

  15

  15

  0:00:00

  0:08:56

• Rondell Graham, M.B.B.S., Head of GI and Liver Pathology at the Mayo Clinic, Predictive and Prognostic Factors in Colon Cancer - episode 15

  Apr 18th 2020

  2020 marks the one hundredth anniversary of the publication of Albert Broder’s landmark paper on tumor grading.
  
  The foundation of what is now called personalized medicine is the idea that not all tumors or all patients are the same. Differences in gene expression and phenotype correlate with outcome and inform how a patient is best treated.
  
  Dr. Rondell Graham is head of gastrointestinal and liver pathology at the Mayo Clinic. He joins us to discuss predictive and prognostic markers in colon cancer - where we've been, the implications of new technologies such as artificial intelligence, as well as the future of targeted therapies.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=EI8MXRL4-5Y7GB9

  15

  15

  0:00:00

  0:30:07

• KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 4

  Apr 18th 2020

  Pharmacogenetics is the study of how people respond differently to drug therapy based on their unique genetic makeup. Genetic variations cause differences in the expression of various enzymes involved in drug metabolism.
  
  Health #economic studies have shown that the use of pharmacogenetic testing in clinical practice results in better outcomes - by a variety of metrics.
  
  Are payors interested in these data? Of course they are. Better outcomes generally save money as well.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=3SL4Y9P5-LTEDN29

  15

  15

  0:00:00

  0:00:58

• KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 3

  Apr 18th 2020

  Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.
  
  Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.
  
  Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=6CW9AB2P-53FPQFR

  15

  15

  0:00:00

  0:00:34

• KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - PREVIEW 2

  Apr 18th 2020

  Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.
  
  Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.
  
  Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=EUA0PSQM-0442T9

  15

  15

  0:00:00

  0:00:57

• KRISTINE ASHCRAFT, CEO OF YOUSCRIPT - Preview 1

  Apr 18th 2020

  How has pharmacogenetic testing evolved over the past 20 years?
  
  We've moved from a very expensive single-gene testing model focused on drug - gene pairs to a more cost-effective multigene panel approach, which can provide significantly more information.
  
  Kristine Ashcraft, CEO of YouScript, which offers a unique combination of pharmacogenetic information and EMR-integrated software, joins us this week on The Personalized Diagnostics Podcast.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=GODRBVOO-12A9K9

  15

  15

  0:00:00

  0:01:17

• Kristine Ashcraft, CEO of YouScript - Episode 14

  Mar 26th 2020

  Pharmacogenetics allows us to identify differences in how people respond to drugs based on their unique genetic makeup.
  
  Genetic variations can affect the function of enzymes involved in drug metabolism, leading to both adverse drug events and toxicity as well as treatment failure.
  
  Routine pharmacogenetic testing has been shown to improve outcomes and save costs but yet it is still underutilized.
  
  Our guest today is out to change that. Kristine Ashcraft is CEO of YouScript, a company offering unique pharmacogenetic information and an Electronic Medical Record integraed software solution.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FCYKQBC7-3VJ9K9

  15

  15

  0:00:00

  0:22:53

• PRASUN MISHRA, PHD, AAPM CORONAVIRUS TASKFORCE - PREVIEW 3

  Mar 26th 2020

  Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT) discussing the unique challenges of a fighting a pandemic in this modern era of globalization, frequent travel and porous national borders in which the world has become "one big home"

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FB1E3UKQ-D50ZFR

  15

  15

  0:00:00

  0:00:20

• Prasun Mishra, PHD, AAPM Coronavirus taskforce - Preview 2

  Mar 26th 2020

  Of the measures available to us to combat #covid19, what should be our priority?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=AYBVGCJK-2FBT9

  15

  15

  0:00:00

  0:00:44

• Prasun Mishra, PHD, AAPM Coronavirus Taskforce - Preview 1

  Mar 26th 2020

  Rahm Emanuel, Chief of Staff to Barack Obama and Mayor of City of Chicago famously said, "Never let a crisis go wasted."
  
  What lessons can we learn from the current Covid-19 crisis?
  
  Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM) and chair of the AAPM Coronavirus Taskforce (ACT)
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=CSKKMLXD-4BCSOR

  15

  15

  0:00:00

  0:01:01

• Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine and chair of the AAPM Coronavirus Taskforce (ACT) - Episode 13

  Mar 17th 2020

  Prasun Mishra, Ph.D. President and CEO of the American Association for Precision Medicine (AAPM)- and chair of the AAPM Coronavirus Taskforce (ACT) joins us on the The Personalized Diagnostics Podcast during this global pandemic.
  
  - Is the novel coronavirus mutating and has a potential to become more contagious?
  
  - Strategies to combat COVID-19?
  
  - Will things get better before they get worse?
  
  - Therapies in development for the novel coronavirus?
  
  - The story behind formation of ACT- AAPMs Coronavirus Taskforce
  
  - What lessons we'll be able to learn from this crisis?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FE4R6WC8-8ILIK9

  15

  15

  0:00:00

  0:30:55

• KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - PREVIEW 3

  Mar 17th 2020

  Will people lose their jobs due to increased #automation and artificial intelligence applications?
  
  "There's a difference between your 'work' and your 'job.' "
  
  The tasks you perform or the #work you do may not be the essence of your job.
  
  "There is a well-known 'Amazon paradox,' which is that as Amazon was increasing the amount of automation in their warehouses and distribution facilities, they were actually increasing their hiring rate."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=DKYI704N-X3WHFR

  15

  15

  0:00:00

  0:00:51

• KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - PREVIEW 2

  Mar 17th 2020

  What are some of the misconceptions surrounding #AI?
  
  A focus on “artificial general intelligence” – the stuff of 1950’s science fiction and concerns of robots taking over the world - “What could you do if you had a machine that is able to act and think and be just like a human,” seems to be going away somewhat.
  
  This #focus is being replaced by realistic concerns and a focus on what it is possible to achieve with specific narrow applications that can solve real problems today - not at some point in the future.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=2908M2D5-RFS3V7V

  15

  15

  0:00:00

  0:00:36

• KATHLEEN WALCH AND RON SCHMELZER, COGNILYTICA - Preview 1

  Mar 17th 2020

  There’s still a lot of misunderstanding surrounding Artificial #Intelligence. When two people talk about #AI, they are quite likely not even talking about the same thing.
  
  To eliminate confusion and facilitate understanding, Cognilytica focuses on the 7 Patterns of AI:
  
  Conversation and Human Interaction
  Recognition
  Patterns and Anomalies
  Predictive Analytics
  Autonomous Systems
  Hyperpersonalization
  Goal Directed Systems
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=ARPF3CAQ-PGGY14I

  15

  15

  0:00:00

  0:01:29

• Kathleen Walch and Ron Schmelzer, Cognilytica - The 7 patterns of AI - Episode 12

  Mar 12th 2020

  Kathleen Walch and Ron Schmelzer, managing partners of the Artificial Intelligence-focused advisory firm Cognilytica
  
  The 7 patterns of #AI
  
  "How can we regulate something that is continuously evolving?"
  
  "Are we focusing on the wrong thing?"
  
  "Where's my flying car?"
  
  and much more... That's this week on the Personalized Diagnostics Podcast

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8C1JBETK-7TLNMI

  15

  15

  0:00:00

  0:34:54

• Rakesh Nagarajan , MD, PhD, Preview 4

  Mar 12th 2020

  One of the promises of precision #medicine is the ability to iterate and incorporate new #information in real-time, rather than having to wait months or years to incorporate new findings into patient treatment decisions.
  
  Have we reached the point where information or data that we observe in patients this week can be used to enhance our ability to treat patients next week?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=7T931Y08-PO2BJ4I

  15

  15

  0:00:00

  0:01:14

• RAKESH NAGARAJAN, MD, PHD - PREVIEW 3

  Mar 12th 2020

  "We're helping customers internalize next generation #sequencing for clinical use... in virtually every market segment."
  
  PierianDx is on a mission to democratize next generation sequencing and #genomics in medicine worldwide.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=53RJDEE7-T5IPB9

  15

  15

  0:00:00

  0:01:03

• RAKESH NAGARAJAN, MD, PHD - PREVIEW 2

  Mar 12th 2020

  In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and #inspiration.
  
  As the metaphorical source of knowledge of art and #science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711):
  
  "A little learning is a dang'rous thing;
  Drink deep, or taste not the Pierian spring."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FYN9NWTH-BUIK9

  15

  15

  0:00:00

  0:00:28

• RAKESH NAGARAJAN, MD, PHD - Preview 1

  Mar 12th 2020

  Despite tremendous advances in #sequencing technologies, informatics and computational power, there still remains a fair degree of subjectivity in genomics and personalized medicine.
  
  It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=CXAGTN27-6RMS4I

  15

  15

  0:00:00

  0:00:39

• Rakesh Nagarajan, MD, PhD, Founder and Executive Chairman of PierianDx - Democratizing Next Generation Sequencing - Episode 11

  Mar 6th 2020

  In Greek mythology, the Pierian Spring of Macedonia was sacred to the Muses. It was believed that drinking from it would bring you great knowledge and inspiration.
  
  As the metaphorical source of knowledge of art and science, it was popularized in Alexander Pope's poem "An Essay on Criticism" (1711):
  
  "A little learning is a dang'rous thing;
  Drink deep, or taste not the Pierian spring:
  
  It takes a team of laboratory scientists, informaticians, variant scientists and physicians to develop and perform assays and formulate treatment decisions for patients.
  
  Rakesh Nagarajan, MD, PhD, of PierianDx joins us to discuss their mission to democratize next generation sequencing.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=10RWKRIM-4R7R2J4

  15

  15

  0:00:00

  0:24:10

• SUNANDINI CHOPRA, PHD, AI FOR THE REST OF US - PREVIEW 3

  Mar 6th 2020

  Will AI applications be limited to research and discovery and development of drugs and diagnostics?
  
  What about post-launch and real-world experience?
  
  "The observational study space is fairly disorganized and could greatly benefit from digitization and machine learning."
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=JEHM1AR9-EI2J4I

  15

  15

  0:00:00

  0:00:54

• SUNANDINI CHOPRA, PHD, AI FOR THE REST OF US - PREVIEW 2

  Mar 6th 2020

  What are patient avatars?
  
  Imagine being able to understand drug efficacy and toxicities without having to involve actual patients.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=C389AVSJ-TQPVI

  15

  15

  0:00:00

  0:00:43

• Sunandini Chopra, PhD, AI For The Rest of Us - Preview 1

  Mar 6th 2020

  All of this talk about #AI can be confusing and intimidating.
  
  What is it?
  How does it work?
  What are applications in #healthcare going to look like?
  Is it going to take away my job?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=HPB257SP-ZTO6R

  15

  15

  0:00:00

  0:00:36

• Sunandini Chopra, PhD, AI for the Rest of Us - Episode 10

  Feb 26th 2020

  All of this talk about Artificial Intelligence can be confusing and intimidating.
  
  What is it?
  How does it work?
  What are applications in healthcare going to look like?
  Is it going to take away my job?
  
  Finally, AI for the Rest of Us. Sunandini Chopra, PhD, joins us this week.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FQSWZL1R-MEU3DI

  15

  15

  0:00:00

  0:22:53

• Michael Bonham , MD, PHD - part II - Preview 3

  Feb 24th 2020

  "It doesn't give you a diagnosis, but it gives you additional information... and the hope is that all pathologists will have the same information."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=1TUM9AMX-P33OW29

  15

  15

  0:00:00

  0:01:02

• Michael Bonham , MD, PHD - part II - Preview 2

  Feb 24th 2020

  "In the same way that when you listen to Pandora, it knows what song you're going to like..."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8QVGB43A-1DOBT9

  15

  15

  0:00:00

  0:00:59

• Michael Bonham , MD, PHD - part II - Preview 1

  Feb 24th 2020

  A confluence of factors will drive the shift to digital pathology.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=CI7CX593-45TGLDI

  15

  15

  0:00:00

  0:01:17

• Michael Bonham MD,PhD, Chief Medical Officer of Proscia - part ii - Have we reached the tipping point? - Episode 9

  Feb 20th 2020

  Michael Bonham MD,PhD, Chief Medical Officer of Proscia is back!
  
  Last time we talked about how pathologists are using the same technology – the light microscope – that they have been for the past 150 years.
  
  The rate of converting to a fully digital system, particularly in the United States, is abysmally low.
  
  With a global shortage of pathologists and regulatory barriers coming down, could we finally be reaching a tipping point?
  
  Could #AI be the missing link that will push us over the edge?
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=H37URBUU-1PP66R

  15

  15

  0:00:00

  0:19:30

• RAFAEL ROSENGARTEN, PHD - PREVIEW 3

  Feb 20th 2020

  What role will AI play in the development of new diagnostics?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8YILI11X-KXOGVI

  15

  15

  0:00:00

  0:00:41

• RAFAEL ROSENGARTEN, PHD - PREVIEW 2

  Feb 20th 2020

  "AI systems in healthcare are going to be under a huge amount of scrutiny."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=U1ZGMOI-6O3CJTT9

  15

  15

  0:00:00

  0:00:52

• Rafael Rosengarten, PhD - Preview 1

  Feb 20th 2020

  We've all heard the hype. But what exactly is AI?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=6SWJVTEP-E5KLNMI

  15

  15

  0:00:00

  0:00:49

• Rafael Rosengarten, PhD, CEO of Genialis and founding member of the Alliance for AI in Healthcare - Episode 8

  Feb 11th 2020

  We've all heard the hype. "There's no area of healthcare that will not be affected by AI." "Those that fail to embrace AI will be left behind by those that do."
  
  But what exactly is AI and how will it impact healthcare?
  
  Rafael Rosengarten is CEO of Genialis and founding member of the Alliance for Artificial Intelligence in Healthcare.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=8EDSAJRJ-GLJ714I

  15

  15

  0:00:00

  0:25:13

• Michael Bonham, MD, PhD, CMO of Proscia, The Promise of Digital Pathology - Episode 7

  Feb 4th 2020

  Pathologists have used largely the same technology to make diagnoses since the late 1800's. Will Pathology be able to go fully digital and enter the 21st century?
  
  Michael Bonham, MD, PhD, Chief Medical Officer of Proscia, joins us to discuss the promise of digital pathology.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=GB08ZKJZ-ESTT9

  15

  15

  0:00:00

  0:18:59

• Clifford Morris, PhD - Preview 3

  Feb 4th 2020

  "So many lab test are just done...and nothing gets done about them."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=H5N22JUV-9CZ0K9

  15

  15

  0:00:00

  0:00:30

• Clifford Morris, PhD - Preview 2

  Feb 4th 2020

  "Having specifics is really the whole point of using AI...not to get general trends."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=XDOYGEH-95CXFLXR

  15

  15

  0:00:00

  0:00:54

• Clifford Morris, PhD - Preview 1

  Feb 4th 2020

  "Metabolomics, we really see as the apogee of all the -omics."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=JWH0GG55-U5L8FR

  15

  15

  0:00:00

  0:01:13

• Clifford Morris, PhD, Laboratory Medicine 2.0 - Episode 6

  Jan 29th 2020

  Laboratory Medicine 2.0 holds much promise, but we have many challenges to overcome before it is a reality.
  
  Will we be able to move away from volume based testing to value based testing? Will we be able to show definitively that patient outcomes and overall levels of health can be improved using laboratory methods? And will we be able to move away from sick care and more towards a system of wellness care?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=6FTGRDFH-95ASJOR

  15

  15

  0:00:00

  0:27:36

• Julie Eggington, MS, PhD - Preview 3

  Jan 29th 2020

  Variants of Uncertain Significance (VUS) cause tension but really shouldn't.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=7TKFI8G1-QFWP14I

  15

  15

  0:00:00

  0:00:33

• Julie Eggington, MS, PhD - Preview 2

  Jan 29th 2020

  "Hang on! genetic variants are actually very, very common."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=DODYB6LT-GAXLXR

  15

  15

  0:00:00

  0:00:59

• Julie Eggington, MS, PhD - Preview 1

  Jan 29th 2020

  We saw tension between investor demands which is profitability and the interests of patients which is accuracy.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=HF2R67EI-TDQUXR

  15

  15

  0:00:00

  0:00:45

• Julie Eggington, MS, PhD, Center for Genomic Interpretation - Episode 5

  Jan 21st 2020

  We can now test anyone for nearly any genetic mutation or alteration. What could possibly go wrong?
  
  Julie Eggington, MS, PhD, co-founder and CEO of Center for Genomic Interpretation joins us this week.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=JV2WZOEK-5A5RK9

  15

  15

  0:00:00

  0:28:41

• Hannah Mamuszka, CEO of Alva10 - Preview 3

  Jan 20th 2020

  What do we have to look forward to in the coming decade?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=BCFJ804R-Z4U0UDI

  15

  15

  0:00:00

  0:00:26

• Hannah Mamuszka, CEO of Alva10 - Preview 2

  Jan 20th 2020

  How can we spur innovation?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FZCB9J5K-L2QPVI

  15

  15

  0:00:00

  0:00:53

• Hannah Mamuszka, CEO of Alva10 - Preview 1

  Jan 20th 2020

  Who is the customer?

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=FZSN3RW5-W29

  15

  15

  0:00:00

  0:00:50

• Hannah Mamuszka, Who is the Customer? - Episode 4

  Jan 17th 2020

  Hannah Mamuszka, CEO of Alva10 tells us how cost-based pricing and the commoditization of diagnostic tests has stifled innovation. The promise of value-based pricing, though, is still very much alive. The key, she says, lies in restructuring the relationship between the diagnostics providers and the payors.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=26UZNC7G-2CU40A4

  15

  15

  0:00:00

  0:29:23

• Roger Klein MD, JD, part ii - Preview 3

  Jan 16th 2020

  "This is a golden age; we're just scratching the surface."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=JKUMW4VV-96YLDI

  15

  15

  0:00:00

  0:00:34

• Roger Klein, MD, JD part ii - Preview 2

  Jan 16th 2020

  "It's actually a good thing from an economics standpoint..." Dr. Roger Klein on whether falling prices can help spur innovation

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=AAXVOM04-L6P3NMI

  15

  15

  0:00:00

  0:00:48

• Roger Klein, MD, JD part ii - Preview 1

  Jan 16th 2020

  “I’m going to have to present a counter view. I think no. These types of tests are going to be commoditized as more providers come into the space.” Roger Klein, MD, JD on if diagnostics providers are going to be able to capture value in the liquid biopsy market

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=9NLYAHBX-NS714I

  15

  15

  0:00:00

  0:00:15

• Roger Klein, MD, JD, part ii, Are we Spiraling to the Bottom? - Episode 3

  Jan 7th 2020

  Are we spiraling to the bottom? Is there any hope for value-based pricing in diagnostics?
  
  Roger D. Klein MD, JD, FCAP is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology (AMP) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes. He is a leading authority on public policies related to the implementation of precision medicine.
  
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=C7Y4H8VH-BNPNWMI

  15

  15

  0:00:00

  0:19:31

• Roger Klein, MD JD - preview 1

  Dec 17th 2019

  Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=G90XT093-FUHAOR

  15

  15

  0:00:00

  0:01:16

• Roger Klein, MD JD, How are Molecular Diagnostcs Tests Reimbursed? - Episode 2

  Dec 17th 2019

  How exactly are molecular diagnostic tests reimbursed?
  
  Is our current coding and reimbursement system up to the task?
  
  How does a new test achieve reimbursement?
  
  Roger D. Klein, MD JD is a former HHS Advisor to FDA, CMS and CDC, and the immediate past chair of the Association for Molecular Pathology’s (AMP’s) Solid Tumors Division. A physician and an attorney, Dr Klein served as an expert and key spokesperson in the lawsuit “Association for Molecular Pathology v. Myriad Genetics, Inc.” in which the U.S. Supreme Court invalidated patents on breast cancer genes.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=E6LNPH9M-U8R529

  15

  15

  0:00:00

  0:26:28

• Dr. Jill Hagenkord, Bridging the Gap Between Health Tech and Health Care - Episode 1

  Dec 9th 2019

  Can we bridge the cultural gap between health tech and health care? What happens when "fail fast, fail often " and "move quickly and break things" meets patient care?
  
  Dr. Jill Hagenkord, the co-founder of MDisrupt and previous Chief Medical Officer at Complete Genomics, Invitae, 23 and Me and Color Genomics joins us.

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=7Z1P1JZN-35QXGVI

  15

  15

  0:00:00

  0:28:09

• Dr. Jill Hagenkord - Preview 3

  Dec 5th 2019

  "We're going to have to make it more patient-centric in the very near future."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=GYT3OTOZ-9AFW29

  15

  15

  0:00:00

  0:00:34

• Dr. Jill Hagenkord - Preview 2

  Dec 4th 2019

  "Think of the difference we could make in healthcare."

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=I14VG1VX-86W29

  15

  15

  0:00:00

  0:00:56

• Dr. Jill Hagenkord - Preview 1

  Dec 4th 2019

  The culture clash between tech and healthcare

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=EC80MQ8M-RO1OR

  15

  15

  0:00:00

  0:01:06

• Welcome - Episode 0

  Dec 4th 2019

  Welcome to the Personalized Diagnostics Podcast.
  
  In the upcoming weeks we are going to be talking to some of the greatest minds and personalities in the diagnostics space – the engine which is driving personalized medicine forward.
  
  Thanks for listening.
  

  episode link (current time)   ☞   https://cast.rocks/hosting/21156/feeds/6MGG9.html?ep=I1KZKGDR-L1H5MI

  15

  15

  0:00:00

  0:01:02